| scholarly article | Q13442814 |
| P50 | author | David C Mamo | Q116792116 |
| Camilo de la Fuente-Sandoval | Q47527086 | ||
| Ariel Graff-Guerrero | Q47527099 | ||
| Pablo León-Ortiz | Q47527122 | ||
| P2093 | author name string | Rafael Favila | |
| Jesús Ramírez-Bermúdez | |||
| Camilo de la Fuente-Sandoval | |||
| Pablo León-Ortiz | |||
| Sylvana Stephano | |||
| P2860 | cites work | The WHO World Health Report 2001 on mental health | Q59596507 |
| Dopamine receptors in human brain: autoradiographic distribution of D2 sites | Q69295011 | ||
| Autoradiographic localization of D1 and D2 dopamine receptors in the human brain | Q70063820 | ||
| Prefrontal cortex projections to the basilar pons in rhesus monkey: implications for the cerebellar contribution to higher function | Q70940629 | ||
| Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo | Q71654418 | ||
| Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia | Q72222106 | ||
| Estimation of metabolite concentrations from localized in vivo proton NMR spectra | Q72319396 | ||
| Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectroscopy study | Q81245412 | ||
| Dopamine-glutamate reciprocal modulation of release and motor responses in the rat caudate-putamen and nucleus accumbens of "intact" animals | Q81459764 | ||
| The dopamine hypothesis of schizophrenia: version III--the final common pathway | Q22242827 | ||
| Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects | Q22248075 | ||
| Schizophrenia: more dopamine, more D2 receptors | Q24630726 | ||
| Gating of information flow within the limbic system and the pathophysiology of schizophrenia | Q28138727 | ||
| Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs | Q28270170 | ||
| Effectiveness of antipsychotic drugs in patients with chronic schizophrenia | Q28273164 | ||
| In vivo differentiation of N-acetyl aspartyl glutamate from N-acetyl aspartate at 3 Tesla | Q28304202 | ||
| N-acetylaspartate synthesis in the brain: mitochondria vs. microsomes | Q28566220 | ||
| Recent advances in the phencyclidine model of schizophrenia | Q29618917 | ||
| High-field proton MRS of human brain | Q30886341 | ||
| Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis | Q31001850 | ||
| What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update. | Q31036551 | ||
| Proton MR spectroscopy of the brain at 3 T: an update | Q31094214 | ||
| Glutamate regulates the spontaneous and evoked release of dopamine in the rat striatum | Q32065533 | ||
| Correction of frequency and phase variations induced by eddy currents in localized spectroscopy with multiple echo times | Q33292069 | ||
| Course of neurocognitive deficits in the prodrome and first episode of schizophrenia | Q33597674 | ||
| 1H-MRS at 4 tesla in minimally treated early schizophrenia | Q33941381 | ||
| Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia | Q33963430 | ||
| Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group | Q34167452 | ||
| Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. | Q34174069 | ||
| Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? | Q34253250 | ||
| Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability | Q34301805 | ||
| Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia | Q34507860 | ||
| Regional gray matter volume abnormalities in the at risk mental state | Q34572449 | ||
| Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America | Q34586836 | ||
| Glutamate receptor dysfunction and schizophrenia | Q34719075 | ||
| Treatment history in the psychosis prodrome: characteristics of the North American Prodrome Longitudinal Study Cohort | Q34727780 | ||
| Electrophysiological interactions between striatal glutamatergic and dopaminergic systems | Q35610984 | ||
| Relapse of paranoid psychotic state in methamphetamine model of schizophrenia | Q35944206 | ||
| Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia | Q36500321 | ||
| Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease | Q36586033 | ||
| Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions | Q36756365 | ||
| Age at onset and cognition in schizophrenia: meta-analysis | Q37606198 | ||
| Proton magnetic resonance spectroscopy (1H-MRS) of the cerebellum in men with schizophrenia | Q39553773 | ||
| The membrane hypothesis of schizophrenia | Q40582385 | ||
| Vulnerability markers in the schizophrenia spectrum: implications for phenomenology, genetics, and the identification of the schizophrenia prodrome | Q40617995 | ||
| The prodromal phase of first-episode psychosis: past and current conceptualizations | Q41091264 | ||
| Regionally specific alterations in membrane phospholipids in children with ADHD: An in vivo 31P spectroscopy study | Q42503917 | ||
| Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis | Q42967481 | ||
| Hippocampal pathology in individuals at ultra-high risk for psychosis: a multi-modal magnetic resonance study. | Q43095693 | ||
| Increased synaptic dopamine function in associative regions of the striatum in schizophrenia | Q43145582 | ||
| Striatal metabolic alterations in non-psychotic adolescent offspring at risk for schizophrenia: a (1)H spectroscopy study | Q43277678 | ||
| N-acetyl aspartate--a neuronal marker? | Q43580304 | ||
| An unfolded map of the cerebellar dentate nucleus and its projections to the cerebral cortex | Q43708970 | ||
| Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum | Q43721371 | ||
| Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H-MRS and tissue segmentation | Q43762654 | ||
| NMDA antagonist effects on striatal dopamine release: positron emission tomography studies in humans | Q43825625 | ||
| High choline concentrations in the caudate nucleus in antipsychotic-naive patients with schizophrenia | Q43843056 | ||
| Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers | Q44201512 | ||
| Ketamine does not decrease striatal dopamine D2 receptor binding in man. | Q44233094 | ||
| Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. | Q44669007 | ||
| Measurement of brain glutamate using TE-averaged PRESS at 3T. | Q44789170 | ||
| 1H MRSI evidence of metabolic abnormalities in childhood-onset schizophrenia | Q44819135 | ||
| 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia | Q44915208 | ||
| Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study. | Q45226292 | ||
| Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study | Q45242209 | ||
| Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. | Q45950519 | ||
| [Glutamate increase in the associative striatum in schizophrenia: a longitudinal magnetic resonance spectroscopy preliminary study]. | Q45973436 | ||
| Dopamine modulation of responses mediated by excitatory amino acids in the neostriatum. | Q46103886 | ||
| Elevated striatal dopamine function linked to prodromal signs of schizophrenia | Q46174418 | ||
| Cerebellar loops with motor cortex and prefrontal cortex of a nonhuman primate. | Q46213380 | ||
| Detection of glutamate in the human brain at 3 T using optimized constant time point resolved spectroscopy | Q46343420 | ||
| Proton MRS in twin pairs discordant for schizophrenia | Q46470298 | ||
| Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. | Q46587017 | ||
| Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study | Q46600035 | ||
| Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum | Q46717751 | ||
| Elevated 3T proton MRS glutamate levels associated with poor Continuous Performance Test (CPT-0X) scores and genetic risk for schizophrenia | Q46772594 | ||
| Assessment of glutamate and glutamine contribution to in vivo N-acetylaspartate quantification in human brain by (1)H-magnetic resonance spectroscopy | Q46787328 | ||
| Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study | Q46816217 | ||
| Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia | Q46840294 | ||
| Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia | Q46974035 | ||
| Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort | Q47997393 | ||
| Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs | Q48161863 | ||
| Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans | Q48170494 | ||
| Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia | Q48283671 | ||
| Single-voxel proton magnetic resonance spectroscopy of the pons and cerebellum in patients with schizophrenia: a preliminary study | Q48319706 | ||
| Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123I]iomazenil | Q48352448 | ||
| Cerebral grey, white matter and csf in never-medicated, first-episode schizophrenia. | Q48373158 | ||
| Neurocognitive performance and negative symptoms: are they equal in explaining disability in schizophrenia outpatients? | Q48465577 | ||
| Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach | Q48466159 | ||
| Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. | Q48577159 | ||
| Endogenous glutamate increases extracellular concentrations of dopamine, GABA, and taurine through NMDA and AMPA/kainate receptors in striatum of the freely moving rat: a microdialysis study. | Q48610336 | ||
| Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy | Q48614993 | ||
| Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex | Q48728126 | ||
| Optimized voxel-based morphometry of gray matter volume in first-episode, antipsychotic-naive schizophrenia | Q48905087 | ||
| 3-D diffusion tensor axonal tracking shows distinct SMA and pre-SMA projections to the human striatum | Q48965527 | ||
| Cerebellar projections to the prefrontal cortex of the primate. | Q49070532 | ||
| Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. | Q51375205 | ||
| Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. | Q51415177 | ||
| The WHO World Health Report 2001 on mental health. | Q51953542 | ||
| Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. | Q55044398 | ||
| Spatial registration and normalization of images | Q57004421 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| patient | Q181600 | ||
| striatum | Q1319792 | ||
| psychosis | Q170082 | ||
| P304 | page(s) | 1781-1791 | |
| P577 | publication date | 2011-04-20 | |
| P1433 | published in | Neuropsychopharmacology | Q2261280 |
| P1476 | title | Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis | |
| P478 | volume | 36 |
| Q49551461 | 7T Proton Magnetic Resonance Spectroscopy of the Anterior Cingulate Cortex in First-Episode Schizophrenia. |
| Q59800560 | A Longitudinal Multimodal Neuroimaging Study to Examine Relationships Between Resting State Glutamate and Task Related BOLD Response in Schizophrenia |
| Q49070894 | A combined diffusion tensor imaging and magnetic resonance spectroscopy study of patients with schizophrenia |
| Q47096361 | Abnormal Concentration of GABA and Glutamate in The Prefrontal Cortex in Schizophrenia.-An in Vivo 1H-MRS Study |
| Q43538712 | Altered Glutamate and Regional Cerebral Blood Flow Levels in Schizophrenia: A 1H-MRS and pCASL study |
| Q33762485 | Altered striatal functional connectivity in subjects with an at-risk mental state for psychosis |
| Q38565386 | An allosteric modulator of metabotropic glutamate receptors (mGluR₂), (+)-TFMPIP, inhibits restraint stress-induced phasic glutamate release in rat prefrontal cortex |
| Q90114169 | An imaging-based risk calculator for prediction of conversion to psychosis in clinical high-risk individuals using glutamate 1H MRS |
| Q36234271 | Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia |
| Q31015147 | Biochemistry of the cingulate cortex in autism: An MR spectroscopy study. |
| Q42505511 | Brain neurochemical and hemodynamic findings in the NY1DD mouse model of mild sickle cell disease |
| Q26770197 | Cardiometabolic risk factors in young people at ultra-high risk for psychosis: A systematic review and meta-analysis |
| Q37693269 | Cerebrospinal fluid glutamate concentration correlates with impulsive aggression in human subjects |
| Q36983379 | Change in brain network topology as a function of treatment response in schizophrenia: a longitudinal resting-state fMRI study using graph theory |
| Q48624926 | Clinical and sociodemographic comparison of people at high-risk for psychosis and with first-episode psychosis |
| Q42674570 | Comment regarding increased striatal glutamate in schizophrenia |
| Q36247410 | Comparison of Metabolite Concentrations in the Left Dorsolateral Prefrontal Cortex, the Left Frontal White Matter, and the Left Hippocampus in Patients in Stable Schizophrenia Treated with Antipsychotics with or without Antidepressants. ¹H-NMR Spect |
| Q37412196 | Connectivity, pharmacology, and computation: toward a mechanistic understanding of neural system dysfunction in schizophrenia |
| Q31108616 | Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics |
| Q36575926 | Contribution of substantia nigra glutamate to prediction error signals in schizophrenia: a combined magnetic resonance spectroscopy/functional imaging study. |
| Q30993265 | Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investigated with Proton Magnetic Resonance Spectroscopy |
| Q36579976 | Cross-sectional Study of Glutamate in the Anterior Cingulate and Hippocampus in Schizophrenia |
| Q37095155 | Deficits in context-dependent adaptive coding of reward in schizophrenia |
| Q37276855 | Deficits in striatal dopamine release in cannabis dependence |
| Q27009237 | Developmental mechanisms in the prodrome to psychosis |
| Q38495807 | Dysplasticity, metaplasticity, and schizophrenia: Implications for risk, illness, and novel interventions. |
| Q37979675 | Early intervention in psychosis: a map of clinical and research initiatives in Latin America. |
| Q33611412 | Effects of Antipsychotic Administration on Brain Glutamate in Schizophrenia: A Systematic Review of Longitudinal 1H-MRS Studies |
| Q57145416 | Effects of N-acetylcysteine on brain glutamate levels and resting perfusion in schizophrenia |
| Q36579965 | Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction |
| Q37622674 | Elevated brain lactate in schizophrenia: a 7 T magnetic resonance spectroscopy study. |
| Q37975281 | Ethical implications for clinical practice and future research in "at risk" individuals. |
| Q36070250 | Examining associations between psychosis risk, social anhedonia, and performance of striatum-related behavioral tasks |
| Q34446463 | GABA and glutamate in schizophrenia: a 7 T ¹H-MRS study |
| Q36992322 | Glutamate and dopamine in schizophrenia: an update for the 21st century |
| Q41646621 | Glutamate as a mediating transmitter for auditory hallucinations in schizophrenia: a (1)H MRS study |
| Q48343342 | Glutamate imaging (GluCEST) reveals lower brain GluCEST contrast in patients on the psychosis spectrum |
| Q91564771 | Glutamate levels in the anterior cingulate cortex in un-medicated first episode psychosis: a proton magnetic resonance spectroscopy study |
| Q37215695 | Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study |
| Q30845062 | Glutamate-mediated excitotoxicity in schizophrenia: a review |
| Q41724967 | Glutamatergic Metabolites, Volume and Cortical Thickness in Antipsychotic-Naive Patients with First-Episode Psychosis: Implications for Excitotoxicity |
| Q30732395 | Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings |
| Q48557473 | Glutamatergic and Neuronal Dysfunction in Gray and White Matter: A Spectroscopic Imaging Study in a Large Schizophrenia Sample |
| Q90748306 | Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging study |
| Q33842716 | Glutamatergic deficit and schizophrenia-like negative symptoms: new evidence from ketamine-induced mismatch negativity alterations in healthy male humans. |
| Q35626964 | Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophrenia |
| Q50132400 | Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention |
| Q90826039 | Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis |
| Q36813471 | Hyperactivity of caudate, parahippocampal, and prefrontal regions during working memory in never-medicated persons at clinical high-risk for psychosis |
| Q30685335 | Imaging glutamate in schizophrenia: review of findings and implications for drug discovery |
| Q37665156 | Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver |
| Q30854782 | Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation |
| Q28083121 | In vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: application to schizophrenia |
| Q30873588 | In vivo magnetic resonance studies reveal neuroanatomical and neurochemical abnormalities in the serine racemase knockout mouse model of schizophrenia |
| Q37131013 | In vivo measurements of glutamate, GABA, and NAAG in schizophrenia |
| Q48948657 | Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia. |
| Q40733200 | Interactions between glutamate, dopamine, and the neuronal signature of response inhibition in the human striatum. |
| Q48019214 | In Vivo Brain Glycine and Glutamate Concentrations in Patients With First-Episode Psychosis Measured by Echo Time-Averaged Proton Magnetic Resonance Spectroscopy at 4T. |
| Q42862248 | Is there evidence for neurotoxicity in the prodromal and early stages of schizophrenia? |
| Q39536837 | Ketamine modulates hippocampal neurochemistry and functional connectivity: a combined magnetic resonance spectroscopy and resting-state fMRI study in healthy volunteers |
| Q39130393 | Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis |
| Q92011148 | Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study |
| Q88261761 | Magnetic Resonance Spectroscopy in Schizophrenia: Evidence for Glutamatergic Dysfunction and Impaired Energy Metabolism |
| Q38207021 | Magnetic resonance imaging in studying schizophrenia, negative symptoms, and the glutamate system |
| Q36113065 | Medial frontal GABA is lower in older schizophrenia: a MEGA-PRESS with macromolecule suppression study |
| Q26865740 | Metabolic alterations associated with schizophrenia: a critical evaluation of proton magnetic resonance spectroscopy studies |
| Q58708360 | Neurofilament light interaction with GluN1 modulates neurotransmission and schizophrenia-associated behaviors |
| Q34552937 | Neuroimaging findings in the at-risk mental state: a review of recent literature |
| Q57144224 | Neurometabolic abnormalities in the associative striatum in antipsychotic-naïve first episode psychosis patients |
| Q89747397 | Neurometabolic correlates of 6 and 16 weeks of treatment with risperidone in medication-naive first-episode psychosis patients |
| Q47280486 | Neuromodulatory Systems and Their Interactions: A Review of Models, Theories, and Experiments |
| Q37730207 | New drugs in psychiatry: focus on new pharmacological targets |
| Q47404190 | Nicotine-induced activation of caudate and anterior cingulate cortex in response to errors in schizophrenia |
| Q34372998 | Preclinical (1)H-MRS neurochemical profiling in neurological and psychiatric disorders |
| Q37682795 | Prediction and prevention of the first psychotic episode: new directions and opportunities. |
| Q47574865 | Prefrontal and Striatal Gamma-Aminobutyric Acid Levels and the Effect of Antipsychotic Treatment in First-Episode Psychosis Patients |
| Q48099270 | Prefrontal and Striatal Glutamate Differently Relate to Striatal Dopamine: Potential Regulatory Mechanisms of Striatal Presynaptic Dopamine Function? |
| Q39464596 | Protein Markers of Neurotransmitter Synthesis and Release in Postmortem Schizophrenia Substantia Nigra |
| Q37141400 | Proton magnetic resonance spectroscopy of the substantia nigra in schizophrenia |
| Q37699352 | Reduced binding potential of GABA-A/benzodiazepine receptors in individuals at ultra-high risk for psychosis: an [18F]-fluoroflumazenil positron emission tomography study |
| Q34048560 | Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia |
| Q37492603 | Reduced γ-Aminobutyric Acid and Glutamate+Glutamine Levels in Drug-Naïve Patients with First-Episode Schizophrenia but Not in Those at Ultrahigh Risk |
| Q30712278 | Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis |
| Q34270086 | Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosis |
| Q46630011 | Reply to ‘Letter in reference to de la Fuente-Sandoval, C. et al. Neuropsychopharmacology 36, 1781–1791, 2011'. |
| Q59129268 | Resting-state gamma-band power alterations in schizophrenia reveal E/I-balance abnormalities across illness-stages |
| Q26767499 | Revisiting the Basic Symptom Concept: Toward Translating Risk Symptoms for Psychosis into Neurobiological Targets |
| Q37625470 | Risperidone Effects on Brain Dynamic Connectivity-A Prospective Resting-State fMRI Study in Schizophrenia |
| Q47800687 | Social isolation stress and chronic glutathione deficiency have a common effect on the glutamine-to-glutamate ratio and myo-inositol concentration in the mouse frontal cortex |
| Q43987270 | Striatal glutamate and the conversion to psychosis: a prospective 1H-MRS imaging study |
| Q33620630 | Subanesthetic ketamine treatment promotes abnormal interactions between neural subsystems and alters the properties of functional brain networks |
| Q47561103 | Substantia nigra ultrastructural pathology in schizophrenia |
| Q36246819 | Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia |
| Q38032249 | Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis |
| Q30395471 | Targeting Glia with N-Acetylcysteine Modulates Brain Glutamate and Behaviors Relevant to Neurodevelopmental Disorders in C57BL/6J Mice. |
| Q38976291 | The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia |
| Q38579616 | The effect of striatal dopamine depletion on striatal and cortical glutamate: A mini-review |
| Q38232366 | The neurobiology and treatment of first-episode schizophrenia |
| Q34073533 | The prodrome and clinical risk for psychotic disorders |
| Q30437188 | The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue |
| Q26860217 | Translating the MAM model of psychosis to humans |
| Q36817154 | Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive |
| Q89515143 | Ultrastructural evidence for glutamatergic dysregulation in schizophrenia |
Search more.